CervoMed

CervoMed Quick Ratio

The Quick Ratio (Acid Test) of CervoMed (CRVO) as of Oct 18, 2026 is 2.82. In the previous year, Quick Ratio (Acid Test) was 6.58 — a change of -57.17% (lower).

Quick Ratio

2.82

YoY

-57.17%

Last updated:

Quick Ratio (Acid Test) of CervoMed is 2025 2.82 . Quick Ratio (Acid Test) of CervoMed was 2024 6.58 . It decreases by -57.17% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CervoMed Stock analysis

What does CervoMed do? CervoMed Inc., headquartered in Boston, Massachusetts, is a clinical-stage biotechnology company operating in the Health Care sector. The company focuses on developing CNS-targeted therapeutics for degenerative brain diseases, with its lead candidate neflamapimod in Phase IIb trials for dementia with Lewy Bodies, early Alzheimer’s, and stroke recovery. Employing 13 full-time staff, CervoMed was formerly known as Diffusion Pharmaceuticals Inc. and went public on 9 November 2016. CervoMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CervoMed stock

Quick Ratio (Acid Test) of CervoMed is 2.82 in 2025.

Quick Ratio (Acid Test) of CervoMed changed from 6.58 to 2.82, representing a -57.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) CervoMed since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s CervoMed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — CervoMed

All Key Metrics — CervoMed